{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:45:23Z","timestamp":1792500323102,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.nefroe.2025.501340","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:24:12Z","timestamp":1761751452000},"page":"501340","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cardiovascular and renal outcomes according to KDIGO stages of chronic kidney disease in the Spanish population: Insights from real-world evidence"],"prefix":"10.1016","volume":"45","author":[{"given":"Rafael","family":"Santamaria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5584-4735","authenticated-orcid":false,"given":"Carlos","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unai","family":"Aranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Capel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Cebri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Alc\u00e1zar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Gorostidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2025.501340_bib0250","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.501340_bib0255","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.nefroe.2018.04.010","article-title":"Chronic kidney disease in Spain: prevalence and impact of accumulation of cardiovascular risk factors","volume":"38","author":"Gorostidi","year":"2018","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.nefroe.2025.501340_bib0260","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.medcli.2020.03.005","article-title":"Prevalence of chronic kidney disease and associated factors in the Spanish population attended in primary care: results of the IBERICAN study","volume":"156","author":"Llisterri","year":"2021","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.nefroe.2025.501340_bib0265","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1053\/j.ajkd.2020.07.013","article-title":"Burden and cost of caring for US veterans with CKD: initial findings from the VA Renal Information System (VA-REINS)","volume":"77","author":"Saran","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefroe.2025.501340_bib0270","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.nefroe.2025.04.009","article-title":"Magnitude of chronic kidney disease in Spain","volume":"45","author":"Santamaria","year":"2025","journal-title":"Nefrologia (Engl Ed)"},{"key":"10.1016\/j.nefroe.2025.501340_bib0275","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.nefro.2021.03.006","article-title":"Epidemiology, clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain","volume":"41","author":"Escobar","year":"2021","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.nefroe.2025.501340_bib0280","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5694\/mja2.51361","article-title":"Competing risks of death and kidney failure in a cohort of Australian adults with severe chronic kidney disease","volume":"216","author":"Jose","year":"2022","journal-title":"Med J Aust"},{"key":"10.1016\/j.nefroe.2025.501340_bib0285","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.jacc.2023.07.012","article-title":"Impaired renal function and major cardiovascular events in young adults","volume":"82","author":"Hussain","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nefroe.2025.501340_bib0290","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.nefroe.2025.501340_bib0295","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.501340_bib0300","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.501340_bib0305","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2025.501340_bib0310","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"Suppl. 6","key":"10.1016\/j.nefroe.2025.501340_bib0315","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/dom.15710","article-title":"A review of the latest real-world evidence studies in diabetic kidney disease: what have we learned about clinical practice and the clinical effectiveness of interventions?","volume":"26","author":"Bonnet","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.nefroe.2025.501340_bib0320","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/dom.14599","article-title":"Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors","volume":"24","author":"Fadini","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.nefroe.2025.501340_bib0325","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/s41598-024-51938-3","article-title":"A comparative study of clinical trial and real-world data in patients with diabetic kidney disease","volume":"14","author":"Kurki","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefroe.2025.501340_bib0330","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/ejhf.2620","article-title":"Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence","volume":"24","author":"Janse","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nefroe.2025.501340_bib0335","doi-asserted-by":"crossref","first-page":"sfad285","DOI":"10.1093\/ckj\/sfad285","article-title":"Optimization of guideline-directed medical therapies in patients with diabetes and chronic kidney disease","volume":"17","author":"Neumiller","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2025.501340_bib0340","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/ndt\/gfac140","article-title":"High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database","volume":"38","author":"Fried","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.501340_bib0345","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.ekir.2022.05.033","article-title":"Low adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines despite clear evidence of utility","volume":"7","author":"James","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.501340_bib0350","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ekir.2020.11.039","article-title":"Adherence to the Kidney Disease: Improving Global Outcomes CKD Guideline in nephrology practice across countries","volume":"6","author":"Stengel","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.501340_bib0355","doi-asserted-by":"crossref","first-page":"e14282","DOI":"10.1111\/eci.14282","article-title":"Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real-world settings: insights from REVEAL-CKD","volume":"54","author":"Tangri","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.nefroe.2025.501340_bib0360","doi-asserted-by":"crossref","first-page":"352","DOI":"10.34067\/KID.0000000000000374","article-title":"Mortality, health care burden, and treatment of CKD: a multinational, observational study (OPTIMISE-CKD)","volume":"5","author":"Tangri","year":"2024","journal-title":"Kidney360"},{"key":"10.1016\/j.nefroe.2025.501340_bib0365","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.recesp.2020.09.014","article-title":"Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study","volume":"75","author":"Sicras-Mainar","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.nefroe.2025.501340_bib0495","unstructured":"eCIE10ES. Electronic edition of CIE-10-ES. 5th edition January 2024. Available at: https:\/\/eciemaps.mscbs.gob.es."},{"key":"10.1016\/j.nefroe.2025.501340_bib0370","unstructured":"The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD): World Health Organization. Available from: https:\/\/www.who.int\/classifications-\/atcddd\/en\/. [Accessed 02 January 2024]."},{"key":"10.1016\/j.nefroe.2025.501340_bib0375","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.nefroe.2025.501340_bib0380","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.nefroe.2025.501340_bib0385","first-page":"302","article-title":"Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease","volume":"34","author":"Gorostidi","year":"2014","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefroe.2025.501340_bib0390","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefroe.2025.501340_bib0395","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nefroe.2025.501340_bib0400","first-page":"219","article-title":"Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Guidelines on Cardiovascular Disease Prevention","volume":"34","author":"Brotons","year":"2022","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.nefroe.2025.501340_bib0405","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin\u2013angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.nefroe.2025.501340_bib0410","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41440-023-01260-8","article-title":"A systematic review and meta-analysis of the clinical impact of stopping renin\u2013angiotensin system inhibitor in patients with chronic kidney disease","volume":"46","author":"Nakayama","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.nefroe.2025.501340_bib0415","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/ndt\/gfaa300","article-title":"Renin\u2013angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease","volume":"36","author":"Walther","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.nefroe.2025.501340_bib0420","doi-asserted-by":"crossref","first-page":"101751","DOI":"10.1016\/j.eclinm.2022.101751","article-title":"Clinical outcomes following discontinuation of renin\u2013angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study","volume":"55","author":"Yang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.nefroe.2025.501340_bib0425","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1159\/000531000","article-title":"Discontinuation of renin\u2013angiotensin system inhibitors and clinical outcomes in chronic kidney disease: a systemic review and meta-analysis","volume":"54","author":"Tang","year":"2023","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2025.501340_bib0430","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000531102","article-title":"Discontinuation of renin\u2013angiotensin\u2013aldosterone system inhibitors secondary to hyperkalemia translates into higher cardiorenal outcomes","volume":"54","author":"An","year":"2023","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.nefroe.2025.501340_bib0435","doi-asserted-by":"crossref","first-page":"sfae021","DOI":"10.1093\/ckj\/sfae021","article-title":"Mortality and hyperkalaemia-associated hospitalisation in patients with chronic kidney disease: comparison of sodium zirconium cyclosilicate and sodium\/calcium polystyrene sulfonate","volume":"17","author":"Onogi","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefroe.2025.501340_bib0440","doi-asserted-by":"crossref","first-page":"102426","DOI":"10.1016\/j.eclinm.2024.102426","article-title":"Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study","volume":"68","author":"Forbes","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.nefroe.2025.501340_bib0445","doi-asserted-by":"crossref","first-page":"eRW0519","DOI":"10.31744\/einstein_journal\/2024RW0519","article-title":"Overview of global healthcare policies for patients with chronic kidney disease: an integrative literature review","volume":"22","author":"Soares","year":"2024","journal-title":"Einstein (Sao Paulo)"},{"key":"10.1016\/j.nefroe.2025.501340_bib0450","doi-asserted-by":"crossref","first-page":"e0001467","DOI":"10.1371\/journal.pgph.0001467","article-title":"National health policies and strategies for addressing chronic kidney disease: data from the International Society of Nephrology Global Kidney Health Atlas","volume":"3","author":"Neuen","year":"2023","journal-title":"PLOS Glob Public Health"},{"key":"10.1016\/j.nefroe.2025.501340_bib0455","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ekir.2024.05.025","article-title":"Prospective study on kidney dysfunction markers and risk for mortality among South Asians","volume":"9","author":"Jagannathan","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.501340_bib0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000520909","article-title":"Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities","volume":"12","author":"Vijay","year":"2022","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.nefroe.2025.501340_bib0465","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.3390\/ijms24032988","article-title":"Chronic kidney disease as a comorbidity in heart failure","volume":"24","author":"Szlagor","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nefroe.2025.501340_bib0470","doi-asserted-by":"crossref","first-page":"e2326230","DOI":"10.1001\/jamanetworkopen.2023.26230","article-title":"Estimated prevalence and testing for albuminuria in US adults at risk for chronic kidney disease","volume":"6","author":"Chu","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.nefroe.2025.501340_bib0475","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.ekir.2020.07.029","article-title":"Impact of CKD progression on cardiovascular disease risk in a contemporary UK cohort of individuals with diabetes","volume":"5","author":"Cabrera","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.501340_bib0480","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ekir.2023.11.015","article-title":"Heart failure guideline-directed medical therapy in end-stage kidney disease: from PARADIGM-HF to clinical practice","volume":"9","author":"Cal\u00ec","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefroe.2025.501340_bib0485","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41440-023-01260-8","article-title":"A systematic review and meta-analysis of the clinical impact of stopping renin\u2013angiotensin system inhibitor in patients with chronic kidney disease","volume":"46","author":"Nakayama","year":"2023","journal-title":"Hypertens Res"},{"key":"10.1016\/j.nefroe.2025.501340_bib0490","doi-asserted-by":"crossref","first-page":"101751","DOI":"10.1016\/j.eclinm.2022.101751","article-title":"Clinical outcomes following discontinuation of renin\u2013angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study","volume":"55","author":"Yang","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425001142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251425001142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:36:26Z","timestamp":1763771786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251425001142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2013251425001142"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.501340","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and renal outcomes according to KDIGO stages of chronic kidney disease in the Spanish population: Insights from real-world evidence","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2025.501340","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"501340"}}